TransEnterix Q4 Earnings Review

By The Wall Street Fox Wednesday, February 25, 2015
Some key highlights from TRXC's Q4 earnings call.
  • On track for submitting 510(k) filing to FDA in mid-2015 (July 1st target)
  • TRXC has not encountered any issues that would impact its timeline.
  • Feedback from SurgiBot operators has been "very positive."
  • "Our experience with training (surgeons to use the SurgiBot) thus far continues to confirm our belief, that the SurgiBot design, which mimics the motions of traditional laparoscopy, reduces overall training complexity and time, by leveraging the surgeons laparoscopic training and experience".
  • The number one drawback of robotic surgery, according to active robotic surgeons, is that they're required to be outside of the sterile field and away from their patients, the second and third most commonly cited drawbacks were the cost and size of the system. (SurgiBot solves all three of these drawbacks)
  • At the society of robotic surgery meeting last week, there were three podium presentations that discussed the SurgiBot system. 
  • Continues to experience high interest in SurgiBot from key opinion leaders.
  • "We continue to get a lot of inbound interest on the SurgiBot and we expect early commercial interest to be high."
  • "We do have quite a bit of interest from surgeons outside of the U.S."
I've been accumulating/following this company since 2013, but after hearing the language used in the Q4 earnings call, I have never felt more compelled to buy more shares for the long run. I will continue to accumulate shares until late 2015/early 2016 prior to FDA approval. My time horizon for this investment is long.
The Wall Street Fox

The Wall Street Fox utilizes fundamental and technical analysis to generate investment ideas. TWSF holds a MBA, and is currently preparing for the Chartered Market Technician (CMT) designation.

No Comment to " TransEnterix Q4 Earnings Review "